Detalhe da pesquisa
1.
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator.
Drug Metab Dispos
; 49(5): 389-394, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632715
2.
Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.
Pulm Pharmacol Ther
; 72: 102097, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800680
3.
In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver.
Xenobiotica
; 44(2): 154-63, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24304169
4.
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 13(6): 611-620, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38389387
5.
A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants.
Clin Pharmacol Drug Dev
; 12(2): 122-131, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495282
6.
Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(11): 1253-1263, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962468
7.
Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.
J Clin Pharmacol
; 62(4): 520-531, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34738233
8.
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Eur J Pharm Sci
; 172: 106155, 2022 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247543
9.
Semen quality of industrial workers occupationally exposed to chromium.
J Occup Health
; 47(5): 424-30, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16230836
10.
Effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031.
J Clin Pharmacol
; 43(12): 1341-9, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14615470
11.
Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
J Clin Pharmacol
; 44(4): 348-58, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15051741
12.
Does erythromycin have anti-inflammatory effects independent of its antimicrobial action?
J Clin Pharmacol
; 52(4): 613-4, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21868717
13.
Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
Am J Ther
; 13(1): 32-42, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16428920
14.
Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects.
Am J Ther
; 11(3): 175-89, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15133532
15.
Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Am J Ther
; 10(5): 356-62, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12975720
16.
Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler.
Am J Ther
; 11(2): 103-13, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-14999362